Skip to Main Content

Jennifer Michlitsch

MD

Pediatric hematologist-oncologist

Dr. Jennifer Michlitsch is a specialist in pediatric blood diseases whose focus is on caring for children with sarcomas, cancerous tumors in bone or other tissues. She has a special interest in treating patients with relapsed sarcomas and other childhood cancers.

Michlitsch's research focuses on new treatments for children with relapsed and treatment-resistant cancers. She has a particular interest in bringing these therapies to all patients at UCSF Benioff Children's Hospital Oakland, regardless of socioeconomic status.

Michlitsch earned her medical degree from the Keck School of Medicine of USC. She completed a residency in pediatrics at Children's Hospital Los Angeles and a fellowship in pediatric hematology and oncology at UCSF Benioff Children's Hospital Oakland.

Michlitsch is a member of the American Society of Pediatric Hematology/Oncology, Children's Oncology Group (COG) and COG's young investigator mentorship program.

  • Education

    Keck School of Medicine of USC, MD, 2001

  • Residencies

    Children's Hospital Los Angeles, Pediatrics, 2014

  • Fellowships

    UCSF, Pediatric Hematology and Oncology, 2009

  • Academic Title

    Associate Professor

Decorative Caduceus

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL...

Improvement in 5-year disease-free survival (DFS) with modified Berlin-Frankfurt-Münster (mBFM) chemotherapy without delayed intensification (DI) part 2 but with inotuzumab ozogamicin, versus full mBFM chemotherapy backbone includ...

Recruiting

More about this study
Decorative Caduceus

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Dia...

Will be assessed in SR-High patients and SR-Avg B-ALL patients who are negative for MRD by flow cytometry but have detectable or indeterminate MRD as measured by high throughput sequencing (HTS) at end of induction (EOI), and pati...

Recruiting

More about this study
Decorative Caduceus

Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or ...

For patients assigned to arms A and B, the investigators will separately estimate the proportion of patients who experience conjugated hyperbilirubinemia > 3mg/dL during induction chemotherapy by arm along with corresponding 95% c...

Recruiting

More about this study
Decorative Caduceus

Evaluation of Immunologic Response Following COVID-19 Vaccination in Children, Adolescents, and...

Will report the proportion of patients with a serologic response to a protocol-approved COVID-19 vaccine, captured using a test for SARS-CoV-2-specific antibodies via immunoassay, and will report a corresponding 95% confidence int...

Recruiting

More about this study
Decorative Caduceus

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philad...

Three-year DFS and 95% confidence intervals (CI) of SR Ph+ ALL patients treated continuous imatinib mesylate with high risk Children's Oncology Group (COG)-ALL chemotherapy backbone or more intensive European (Es)PhALL chemotherap...

Recruiting

More about this study
Decorative Caduceus

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Re...

Response rates will be calculated as the percent of evaluable patients who are responders, and confidence intervals will be constructed using the Wilson score interval method.

Recruiting

More about this study
See all clinical trials

Where I see patients (5)

    Feeling at home

    From bedside bingo to therapy dogs, we're here to help kids smile and feel more like themselves.

    Visit Child Life services

    Share